206 related articles for article (PubMed ID: 17606736)
1. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy.
Sadun RE; Sachsman SM; Chen X; Christenson KW; Morris WZ; Hu P; Epstein AL
Clin Cancer Res; 2007 Jul; 13(13):4016-25. PubMed ID: 17606736
[TBL] [Abstract][Full Text] [Related]
2. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
Liu A; Hu P; Khawli LA; Epstein AL
J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
[TBL] [Abstract][Full Text] [Related]
3. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
4. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection.
Elloso MM; Scott P
J Immunol; 1999 Jun; 162(11):6708-15. PubMed ID: 10352289
[TBL] [Abstract][Full Text] [Related]
5. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model.
Leung J; Suh WK
J Immunol; 2013 Jun; 190(12):6651-61. PubMed ID: 23686485
[TBL] [Abstract][Full Text] [Related]
6. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
7. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
8. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
9. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Dong H; Strome SE; Salomao DR; Tamura H; Hirano F; Flies DB; Roche PC; Lu J; Zhu G; Tamada K; Lennon VA; Celis E; Chen L
Nat Med; 2002 Aug; 8(8):793-800. PubMed ID: 12091876
[TBL] [Abstract][Full Text] [Related]
11. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T
Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
[TBL] [Abstract][Full Text] [Related]
12. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.
Salceda S; Tang T; Kmet M; Munteanu A; Ghosh M; Macina R; Liu W; Pilkington G; Papkoff J
Exp Cell Res; 2005 May; 306(1):128-41. PubMed ID: 15878339
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure.
Leifeld L; Trautwein C; Dumoulin FL; Manns MP; Sauerbruch T; Spengler U
Am J Pathol; 1999 Jun; 154(6):1711-20. PubMed ID: 10362796
[TBL] [Abstract][Full Text] [Related]
14. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
[TBL] [Abstract][Full Text] [Related]
16. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
17. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
19. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
Smythe JA; Fink PD; Logan GJ; Lees J; Rowe PB; Alexander IE
J Immunol; 1999 Sep; 163(6):3239-49. PubMed ID: 10477593
[TBL] [Abstract][Full Text] [Related]
20. B7-1, but not CD28, is crucial for the maintenance of the CD4+ T cell responses in human leprosy.
Schlienger K; Uyemura K; Jullien D; Sieling PA; Rea TH; Linsley PS; Modlin RL
J Immunol; 1998 Sep; 161(5):2407-13. PubMed ID: 9725237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
